hiPS-derived renal progenitor cell therapy (Kyoto University/Astellas Pharma)

N/A

Report date: 2025/03/20 15:08:28

Base Information

Drug NamehiPS-derived renal progenitor cell therapy (Kyoto University/Astellas Pharma)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Kidney stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRenal Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesKyoto UniversityAstellas Pharma Inc
Inactive CompaniesN/A
Active IndicationsRenal Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A